Ms. Heather Medwick reports

CYTOPHAGE TECHNOLOGIES REPORTS SUCCESSFUL E. COLI CONTAINMENT IN EU PILOT STUDY FOR AVIPHAGE

Cytophage Technologies Ltd. today released promising results of the European pilot study of AviPhage, its bacteriophage-based poultry health product, in broiler chickens (see press release April 30, 2025).

The purpose of this pilot study was to generate data on the efficacy of AviPhage on European poultry and evaluate the study protocol in a working barn setting. The study compared the AviPhage-treated study group to the control group that received preventative standard antibiotics in respect to lowering E. coli bacteria levels. Over all, the study results show that AviPhage was comparable withh or outperformed antibiotics in key performance indicators.

AviPhage is a bacteriophage-based poultry solution that has been developed by Cytophage to promote gut health, increase bird weight, improve feed conversion ratio, decrease signs of disease and reduce mortality, becoming an alternative to preventative antibiotic use.

Results highlights:

• E. Coli containment: AviPhage effectively restricted E. coli from migrating from the intestines into the bloodstream, tissues and organs -- critical to reducing disease progression.
• Effective mortality control without antibiotics: Mortality in the AviPhage group was statistically equivalent to that of the standard antibiotic-treated control group -- a meaningful result demonstrating AviPhage's ability to protect bird health without relying on antibiotics and supporting its potential as a safer alternative.
• Improved weight uniformity: AviPhage-treated birds showed more consistent individual weights, providing producers with greater yield predictability.
• Bird health: Chickens treated with AviPhage remained healthy throughout the trial, without signs of E. coli-related illness and without the use of antibiotics.

Next steps

The follow-up trial, launched in early July, incorporated enhanced study design and operational controls. The study compares AviPhage-treated birds with an untreated, non-antibiotic control group and is expected to conclude in August. Results are anticipated thereafter.

"We are highly encouraged by these outcomes," said Dr. Steven Theriault, chief executive officer of Cytophage. "AviPhage kept birds healthy, controlled E. coli and matched antibiotic-level mortality rates -- all without antibiotics. We are confident AviPhage will demonstrate further advantages under optimized conditions."

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast-track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR).

The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.